PTEN and invasive breast carcinoma: In the TCGA pan-cancer cohort, PTEN alterations occur most frequently in uterine corpus endometrial carcinoma (UCEC) (66.54% of all UCEC samples; data not shown), while FLG-AS1 amplification is most prevalent in hepatocellular carcinoma, lung adenocarcinoma and breast invasive carcinoma (Figure S2), with only two UCEC samples harboring an amplification in this lncRNA.